Creation of atrial communication in patients with pulmonary hypertension: from balloon atrioseptostomy to atrial flow regulator

Pulmonary hypertension (PH) affects about 1 % of the world’s population, with a three-year survival rate of 70 %. The pathogenetic causes of death are the remodeling of the pulmonary arteries (PA) and the development of right ventricular heart failure (HF), therefore, the main goal of the treatment of pulmonary arterial hypertension (PAH) is to relieve the right chambers of the heart by reducing the pressure in the PA. For this purpose, it is possible to prescribe specific drug therapy to the patient, and in severe cases, surgical intervention — lung transplantation or cardiopulmonary organ complex. However, recently, due to the development and improvement of endovascular methods of treatment of PH, palliative endovascular interventions on the atrial septum are increasingly used, which have undergone significant changes over the past decades. This article presents a literature review of all currently available palliative X-ray endovascular methods for the treatment of PAH, as well as PH developed in patients with left ventricular HF. Objective. The purpose of the review is to assess the role of X-ray endovascular intervention in the treatment of PH.

1. Lehner A, Schulze-Neick I, Fischer M, Fernandez-Rodriguez S, Ulrich S, Haas N et al. The creation of an interatrial right-to-left shunt in patients with severe, irreversible pulmonary hypertension: rationale, devices, outcomes. Curr Cardiol Rep. 2019;21(5):31. doi:10.1007/s11886-019-1118-8

2. Hoeper MM, Ghofrani HA, Grünig E, Klose H, Olschewski H, Rosenkranz S. Pulmonary hypertension. Dtsch Arztebl Int. 2017;114(5):73–84. doi:10.3238/arztebl.2017.0073

3. Humbert M, Kovacs G, Hoeper M, Badagliacca R, Berger R, Brida M et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618–3731. doi:10.1093/eurheartj/ehac237

4. Kim D, George MP. Pulmonary hypertension. Med Clin North Am. 2019;103(3):413–423. doi:10.1016/j.mcna.2018.12.002

5. Rajeshkumar R, Pavithran S, Sivakumar K, Vettukattil J. Atrial septostomy with a predefined diameter using a novel occlutech atrial flow regulator improves symptoms and cardiac index in patients with severe pulmonary arterial hypertension. Catheter Cardiovasc Interv. 2017;90(7):1145–1153. doi:10.1002/ccd.27233

6. Rich S, Lam W. Atrial septostomy as palliative therapy for refractory primary pulmonary hypertension. Am J Cardiol. 1983;51(9):1560–1561. doi:10.1016/0002-9149(83)90678-1

7. Rozkovec A, Montanes P, Oakley CM. Factors that influence the outcome of primary pulmonary hypertension. Br Heart J. 1986;55(5):449–458. doi:10.1136/hrt.55.5.449

8. Alekyan BG, Gorbachevskiy SV, Pursanov MG, Dadabaev GM, Pardaev DB, Nishonov NA. Stent fenestration of atrial septumin idiopathic pulmonary arterial hypertension. Russ J Thoracicand Cardiovasc Surg. 2016;58(5):287–290. In Russian.

9. Gorbachevsky SV, Belkina MV, Pursanov MG, Tkacheva AV, Vladimirskaya MA, Koroleva NI et al. Atrial septostomy as a long bridge to lung transplantation in patients with pulmonary arterial hypertension. J Cardiovasc Surg. 2012;53(2):11.

10. Malaczynska-Rajpal K, Araszkiewicz A, MularekKubzdela T. Balloon atrial septostomy in pulmonary arterial hypertension: a beneficial effect on the control of rhythm abnormalities. Cardiol J. 2016;23(5):539–540. doi:10.5603/CJ.2016.0075

11. Stümper O, Gewillig M, Vettukattil J, Budts W, Chessa M, Chaudhari M et al. Modified technique of stent fenestration of the atrial septum. Heart. 2003;89(10):1227–1230. doi:10.1136/heart.89.10.1227

12. Aldoss O, Divekar A. Modified technique to create diabolo stent configuration. Pediatr Cardiol. 2016;37(4):728–733. doi:10.1007/s00246-015-1339-6

13. Maschietto N, Baird C, Porras D. Percutaneous intraluminal downsizing of systemic-to-pulmonary artery shunts: a novel application of the Diabolo stent technique-Case series and description of the technique. Catheter Cardiovasc Interv. 2020; 95(3):471–476. doi:10.1002/ccd.28598

14. Dell’avvocata F, Rigatelli G, Cardaioli P, Giordan M. Home-made fenestrated amplatzer occluder for atrial septal defect and pulmonary arterial hypertension. J Geriatr Cardiol. 2011;8(2):127–129. doi:10.3724/SP.J.1263.2011.00127

15. Samuel BP, Al-Khatib Y, Peacock-McKenzie CEL, Girgis RE, Vettukattil JJ. Use of Occlutech fenestrated atrial septal defect occluder in ASD-associated pulmonary arterial hypertension. Cardology Today. 2017;15(5):4.

16. McLennan D, Ivy D, J Morgan G. Transvenous implantation of the Occlutech atrial flow regulator: preliminary results from swine models. Congenit Heart Dis. 2019;14(5):819–831. doi:10.1111/chd.12816

17. Patel MB, Samuel BP, Girgis RE, Parlmer MA, Vettukattil JJ. Implantable atrial flow regulator for severe, irreversible pulmonary arterial hypertension. EuroIntervention. 2015;11(6):706– 709. doi:10.4244/EIJY15M07_08

18. Vanhie E, VandeKerckhove K, A Haas N, De Wolf D. Atrial flow regulator for drug-resistant pulmonary hypertension in a young child. Catheter Cardiovasc Interv. 2021;97(6):830–834. doi:10.1002/ccd.29590

19. Sivakumar K, Rohitraj G, Rajendran M, Thivianathan N. Study of the effect of Occlutech atrial flow regulator on symptoms, hemodynamics, and echocardiographic parameters in advanced pulmonary arterial hypertension. Pulm Circ. 2021;11(1):2045894021989966. doi:10.1177/2045894021989966

20. Groenewegen A, Rutten FH, Mosterd A, Hoes A. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342–1356. doi:10.1002/ejhf.1858

21. Chahine J, Alvey H. Left Ventricular Failure. StatPearls [Internet]. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537098/

22. Rosenkranz S, Gibbs JSR, Wachter R, De Marco T, Vonk-Noordegraaf A, Vachiéry JL. Left ventricular heart failure and pulmonary hypertension. Eur Heart J. 2016;37(12):942–954. doi:10.1093/eurheartj/ehv512

23. Bakhshaliyev N, Celikkale İ, Enhoş A, Karaçöp E, Uluganyan M, Özdemir R. Impact of atrial flow regulator (AFR) implantation on 12-month mortality in heart failure: insights from a single site in the PRELIEVE study. Herz. 2022;47(4):366–373. doi:10.1007/s00059-021-05063-w

24. Paitazoglou C, Bergmann M, Özdemir R, Pfister R, Bartunek J, Kilic T et al. One-year results of the first-in-man study investigating the atrial flow regulator for left atrial shunting in symptomatic heart failure patients: the PRELIEVE study. Eur J Heart Fail. 2021;23(5):800–810. doi:10.1002/ejhf.2119

25. Hansmann G, Sabiniewicz A, Sabiniewicz R. Atrial flow regulator for postcapillary pulmonary hypertension: first-in-human transcatheter AFR device implantations in RCM. JACC Case Rep. 2022;4(14):878–884. doi:10.1016/j.jaccas.2022.05.010

26. Rodés-Cabau J, Bernier M, Amat-Santos I, Ben Gal T, Nombela-Franco L, García Del Blanco B et al. Interatrial shunting for heart failure: early and late results from the first-in-human experience with the V-Wave system. JACC Cardiovasc Interv. 2018;11(22):2300–2310. doi:10.1016/j.jcin.2018.07.001

27. Del Trigo M, Bergeron S, Bernier M, Amat-Santos IJ, Puri R, Campelo-Parada F et al. Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction: a safety and proof-of-principle cohort study. Lancet. 2016;387(10025):1290–1297. doi:10.1016/s0140-6736(16)00585-7

28. RELIEVE-HF clinical study [cited 2023 Feb 04]. Available from: https://www.relieve-hf.info/